X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs CADILA HEALTHCARE - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA CADILA HEALTHCARE DISHMAN PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 25.1 35.2 71.4% View Chart
P/BV x 3.3 9.1 37.0% View Chart
Dividend Yield % 0.7 0.7 98.3%  

Financials

 DISHMAN PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
CADILA HEALTHCARE
Mar-16
DISHMAN PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs374454 82.4%   
Low Rs129305 42.3%   
Sales per share (Unadj.) Rs197.896.1 205.8%  
Earnings per share (Unadj.) Rs21.214.9 142.6%  
Cash flow per share (Unadj.) Rs34.717.8 194.8%  
Dividends per share (Unadj.) Rs2.003.20 62.5%  
Dividend yield (eoy) %0.80.8 94.2%  
Book value per share (Unadj.) Rs179.952.3 344.1%  
Shares outstanding (eoy) m80.691,023.74 7.9%   
Bonus/Rights/Conversions -FV5:1-  
Price / Sales ratio x1.33.9 32.2%   
Avg P/E ratio x11.925.5 46.5%  
P/CF ratio (eoy) x7.221.3 34.0%  
Price / Book Value ratio x1.47.3 19.3%  
Dividend payout %9.421.5 43.8%   
Avg Mkt Cap Rs m20,306388,458 5.2%   
No. of employees `0000.815.4 5.4%   
Total wages/salary Rs m5,35513,317 40.2%   
Avg. sales/employee Rs Th19,252.76,371.1 302.2%   
Avg. wages/employee Rs Th6,459.5862.4 749.0%   
Avg. net profit/employee Rs Th2,064.1986.1 209.3%   
INCOME DATA
Net Sales Rs m15,96198,376 16.2%  
Other income Rs m265941 28.2%   
Total revenues Rs m16,22699,317 16.3%   
Gross profit Rs m4,10323,829 17.2%  
Depreciation Rs m1,0913,022 36.1%   
Interest Rs m944486 194.3%   
Profit before tax Rs m2,33421,262 11.0%   
Minority Interest Rs m0-300 0.0%   
Prior Period Items Rs m15 22.0%   
Extraordinary Inc (Exp) Rs m0-25 0.0%   
Tax Rs m6245,716 10.9%   
Profit after tax Rs m1,71115,226 11.2%  
Gross profit margin %25.724.2 106.1%  
Effective tax rate %26.726.9 99.4%   
Net profit margin %10.715.5 69.3%  
BALANCE SHEET DATA
Current assets Rs m11,01844,376 24.8%   
Current liabilities Rs m9,51734,071 27.9%   
Net working cap to sales %9.410.5 89.8%  
Current ratio x1.21.3 88.9%  
Inventory Days Days11054 205.2%  
Debtors Days Days3562 55.9%  
Net fixed assets Rs m16,30447,896 34.0%   
Share capital Rs m1611,024 15.8%   
"Free" reserves Rs m12,90748,746 26.5%   
Net worth Rs m14,51653,519 27.1%   
Long term debt Rs m4,1898,964 46.7%   
Total assets Rs m29,805100,163 29.8%  
Interest coverage x3.544.7 7.8%   
Debt to equity ratio x0.30.2 172.3%  
Sales to assets ratio x0.51.0 54.5%   
Return on assets %8.915.7 56.8%  
Return on equity %11.828.4 41.4%  
Return on capital %17.534.3 51.1%  
Exports to sales %24.845.3 54.8%   
Imports to sales %3.75.9 63.0%   
Exports (fob) Rs m3,95644,537 8.9%   
Imports (cif) Rs m5965,838 10.2%   
Fx inflow Rs m4,95244,881 11.0%   
Fx outflow Rs m6979,069 7.7%   
Net fx Rs m4,25535,812 11.9%   
CASH FLOW
From Operations Rs m2,78619,938 14.0%  
From Investments Rs m-1,529-9,039 16.9%  
From Financial Activity Rs m-941-9,527 9.9%  
Net Cashflow Rs m3161,372 23.1%  

Share Holding

Indian Promoters % 61.4 74.8 82.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 8.3 44.6%  
FIIs % 12.7 5.9 215.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 11.0 200.9%  
Shareholders   46,261 44,069 105.0%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   AUROBINDO PHARMA  MERCK LTD  NOVARTIS  FULFORD INDIA  ORCHID PHARMA LTD  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS